Matching patients to optimal treatments through molecular age signatures

Clinicians often use a patient’s age to inform treatment decisions in a wide range of clinical scenarios. However, chronological age is an unreliable predictor of individual’s risk of disease of treatment-related adverse outcomes. An individual’s rate of aging is strongly influenced by environmental, genetic, and lifestyle factors which are not accounted for by chronological age alone. In contrast, biomarkers of molecular age provide a snapshot of the overall health and resiliency of the body, helping physicians to better know their patients and more accurately predict their health risks.

How we think of aging

Decline in physiologic reserve is a natural part of aging and is responsible for an increase in risk of disease and adverse treatment outcomes. HealthSpan Diagnostics has developed a test that quantifies physiologic reserve by measuring biomarkers that cause cellular aging. Expression of these biomarkers is personalized and based on genetic, lifestyle, and environmental factors. Individuals of the same age can have drastically different molecular age signatures and unique risk profiles.
Patient’s molecular age is more than just a number. It helps match patients to therapies and clinical trials — giving doctors and patients powerful actionable insights for navigating care.

P16 Testing:

Expression of p16 aging biomarker is a powerful predictor of patients physiologic reserve and is being clinically validated in multiple clinical settings.

AKI-Sapere:

AKI-SapereTM, is being clinically validated in a cardiovascular disease setting to identify patients  at high risk for acute kidney injury, adverse cardiac outcomes, rehospitalization and death.

Become a Partner

HealthSpan Dx is seeking partnerships with clinicians, pharma companies, and academic researchers that would benefit from our expertise in measuring molecular age signatures in patients across various diseases to uncover patient risk.